Publications by authors named "S H Abhyankar"
Introduction: Late-onset Alzheimer's Disease (LOAD) is the predominant form of Alzheimer's disease (AD), and apolipoprotein E (APOE) ε4 is a strong genetic risk factor for LOAD. As an integral part of the central nervous system, the retina displays a variety of abnormalities in LOAD. Our study is focused on age-dependent retinal impairments in humanized APOE4-knock-in (KI) and APOE3-KI mice developed by the Model Organism Development and Evaluation for Late-Onset Alzheimer's Disease (MODEL-AD) consortium.
View Article and Find Full Text PDFCharacterization of the Ocular Phenotype in a Col4a3 Knockout Mouse Model of Alport Syndrome.
Invest Ophthalmol Vis Sci
December 2024
Purpose: Alport syndrome (AS) is a genetic condition caused by a dysfunctional collagen (IV) α3α4α5 heterotrimer, leading to basement membrane instability and, ultimately, abnormalities in the kidney, inner ear, and eyes. This study aimed to characterize ocular pathology of AS by focusing on inflammatory and fibrotic markers.
Methods: Col4a3tm1Dec knockout (KO) mice eyes were evaluated for the localization of collagen (IV) α3 and collagen (IV) α4, then stained for transforming growth factor-β1 (TGF-β1), TGF-β2, connective tissue growth factor (CTGF), and β-catenin.
Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review.
Transpl Immunol
December 2024
Article Synopsis
- Idiopathic Pneumonia Syndrome (IPS) is a serious complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT), potentially leading to high morbidity and mortality, often due to inflammatory damage.
- This study examines the use of Ruxolitinib, a JAK inhibitor, combined with corticosteroids (CS) in treating IPS compared to standard corticosteroid treatment, through a case series of three patients and a systematic review of previous literature involving 346 cases.
- Results indicated that the three patients treated with Ruxolitinib and CS showed significant improvement without mortality linked to IPS, and the systematic review supported these findings across a diverse patient demographic.
Article Synopsis
- The SIERRA trial aimed to improve outcomes for older patients with relapsed or refractory acute myeloid leukemia (RR AML) by comparing a new treatment, I-apamistamab, against standard care before bone marrow transplant.
- The study involved 153 patients, with results showing a significantly higher durable complete remission (dCR) rate of 17.1% for the I-apamistamab group compared to 0% for the conventional care group.
- Although the overall survival rates were similar between the two groups, the I-apamistamab regimen exhibited more promise for achieving long-lasting remission with similar levels of severe side effects.
Background: The LinSca1c-Kit (LSK) fraction of the bone marrow (BM) comprises multipotent hematopoietic stem cells (HSCs), which are vital to tissue homeostasis and vascular repair. While diabetes affects HSC homeostasis overall, the molecular signature of mRNA and miRNA transcriptomic under the conditions of long-standing type 2 diabetes (T2D;>6 months) remains unexplored.
Methods: In this study, we assessed the transcriptomic signature of HSCs in db/db mice, a well-known and widely used model for T2D.